Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 13/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 13/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11163458 | 0.82 | NISCH (0.68) | MAOAMAOBNISCHADRA2CADRA2B | |
| SCHEMBL3173010 | 0.81 | MAOA (0.71) | MAOAMAOBNISCHADRA2CADRA2B | |
| Hydrochloric Acid SCHEMBL11164250 | 0.81 | NISCH (0.66) | MAOAMAOBNISCHADRA2CADRA2B | |
| Phenamazoline SCHEMBL936813 | 0.81 | MAOA (1.00) | MAOAMAOBNISCHADRA2CADRA2B | |
| SCHEMBL11259524 | 0.81 | MAOA (0.60) | MAOAMAOBNISCHADRA2CADRA2B | |
| Hydrochloric Acid SCHEMBL11254132 | 0.79 | MAOA (0.59) | MAOAMAOBNISCHADRA2CADRA2B | |
| SCHEMBL11257533 | 0.79 | MAOA (0.62) | MAOAMAOBNISCHADRA2CADRA2B | |
| Hydrochloric Acid SCHEMBL11259136 | 0.78 | MAOA (0.61) | MAOAMAOBNISCHADRA2CADRA2B | |
| SCHEMBL29920874 | 0.77 | MAOA (0.56) | MAOAMAOBNISCHADRA2CADRA2B | |
| SCHEMBL3172126 | 0.77 | MAOA (0.56) | MAOAMAOBNISCHADRA2CADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173720-A2 | 2-IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | claimed |
| CN-101687812-A | The 2-imidazolinium compounds that trace amine associated receptors (TAAR) is had good affinity | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | claimed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | claimed |
| WO-2009003868-A2 | 2 -IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | claimed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-2173720-A2 | 2-IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687812-A | The 2-imidazolinium compounds that trace amine associated receptors (TAAR) is had good affinity | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| WO-2009003868-A2 | 2 -IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018180-A1 | 2-IMIDAZOLINES | TAAR1, TAAR5, NPY1R | MAOA 67/4885MAOB 81/4885NISCH 2014/4885 |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | MAOA 300/4885MAOB 413/4885NISCH 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.